TP026/#1435 Phase 3 study of efficacy & safety of Olvi-Vec and platinum-doublet + bevacizumab compared to platinum-doublet + bevacizumab in platinum-resistant/refractory ovarian cancer (ONPRIME; GOG-3076) [NCT05281471]
Robert W Holloway, P. Thaker, A. Mendivil, Sarfraz Ahmad, M. Bell, S. Chambers, John K. Chan, R. Coleman, Sarah Crafton, Erin P. Crane, R. Eskander, Karen Finkelstein, W. Graybill, T. Herzog, V. John, L. Landrum, A. Leiser, Michael Mchale, Rachel Miller, B. Monk, K. Moore, D. O’Malley, T. Reid, D. Richardson, D. Silasi, J. Sunde, K. Tewari
{"title":"TP026/#1435 Phase 3 study of efficacy & safety of Olvi-Vec and platinum-doublet + bevacizumab compared to platinum-doublet + bevacizumab in platinum-resistant/refractory ovarian cancer (ONPRIME; GOG-3076) [NCT05281471]","authors":"Robert W Holloway, P. Thaker, A. Mendivil, Sarfraz Ahmad, M. Bell, S. Chambers, John K. Chan, R. Coleman, Sarah Crafton, Erin P. Crane, R. Eskander, Karen Finkelstein, W. Graybill, T. Herzog, V. John, L. Landrum, A. Leiser, Michael Mchale, Rachel Miller, B. Monk, K. Moore, D. O’Malley, T. Reid, D. Richardson, D. Silasi, J. Sunde, K. Tewari","doi":"10.1136/ijgc-2022-igcs.535","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":105919,"journal":{"name":"E-Posters (Trials In Progress)","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"E-Posters (Trials In Progress)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2022-igcs.535","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
